Treatment of symptoms associated with coronavirus-induced acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)
The project aims to optimize two types of antibodies: anti-C5a and anti-C5aR1, previously developed in the laboratory. The aims are: (1) inhibit the signaling cascade of C5a-C5aR1 in the immune cells, which trigger the uncontrolled inflammation leading to the death of patients infected by coronavirus; and (2) facilitate its management in the lung tissue by means of nebulizers or inhalers.

Principal Investigators: M. Cristina Vega y Santiago Rodríguez de Córdoba (CIB)

We use cookies on this site to improve your user experience. More info. ACEPTAR

Aviso de cookies